

## Radiological Case Report / Caso Clínico

## Hepatic Artery Pseudoaneurysm After Liver Transplantation - Endovascular Treatment with Stent Graft

### *Pseudoaneurisma da Artéria Hepática Após Transplante - Tratamento Endovascular com Stent Coberto*

Nuno Miguel Ferreira Campos<sup>1</sup>, Paulo Donato<sup>1,2</sup>

<sup>1</sup>Department of Medical Imaging - Coimbra Hospital and University Centre (CHUC), Coimbra, Portugal

<sup>2</sup>Faculty of Medicine of the University of Coimbra (FMUC), Coimbra, Portugal

**Address**

Nuno Miguel Ferreira Campos  
Serviço de Imagem Médica  
Centro Hospitalar e Universitário de Coimbra  
Praceta Professor Mota Pinto  
3000-076 Coimbra, Portugal  
e-mail: nunocampos.bf@gmail.com

**Received:** 23/10/2022

**Accepted:** 15/11/2022

**Published:** 30/04/2023

© Author(s) (or their employer(s)) and ARP 2023. Re-use permitted under CC BY-NC. No commercial re-use.

**Abstract**

Hepatic artery pseudoaneurysms (HAP) after liver transplantation are rare and associated with high mortality. Different treatment options exist for HAP, which include surgical intervention, radiological coil embolization or stenting and retransplantation.

We describe a case of a patient presenting with HAP after a liver transplantation, that was successfully treated with stent grafting, allowing preservation of the arterial flow and minimal risk of organ failure.

Endovascular intervention of HAP should be regarded as the treatment of choice, either in symptomatic or in asymptomatic patients.

**Keywords**

Hepatic artery; Pseudoaneurysm; Stent; Vascular grafting; Liver transplantation.

**Resumo**

Pseudoaneurismas da artéria hepática (PAH) após transplante hepático são raros e estão associados a elevada mortalidade. Existem diferentes opções terapêuticas para os PAH, incluindo a intervenção cirúrgica, tratamento endovascular através de embolização com coils ou aplicação de stents e ainda re-transplantação.

Descrevemos um caso de um paciente que desenvolveu um PAH após transplantação hepática, tratado com sucesso através de colocação de um stent coberto, permitindo a preservação do fluxo arterial hepático e assim um risco mínimo de falência do transplante.

O tratamento endovascular de PAH deve ser encarado como opção terapêutica de primeira linha, quer em pacientes sintomáticos quer em doentes assintomáticos.

**Palavras-chave**

Artéria hepática; Pseudoaneurisma; Stent; Transplante hepático.

## Introduction

Hepatic artery pseudoaneurysms (HAP) after liver transplantation are rare, with reported incidence between 1 and 2%.<sup>1</sup> They usually occur within the first month after transplantation and are commonly associated with localized infection.<sup>2</sup> The mortality associated with HAP formation is high (69%), particularly if surgical intervention is performed as an emergency following acute hemorrhage.<sup>2</sup>

HAP can be classified as intrahepatic or extrahepatic according to its location. Intrahepatic pseudoaneurysms may result from previous procedures, such as liver biopsy and biliary drainage, whereas extrahepatic pseudoaneurysms are commonly associated with localized infection or anastomotic complications.<sup>2</sup>

Different treatment options exist for HAP, which include surgical resection and revascularization, radiological coil embolization or stenting and retransplantation.<sup>1</sup>

## Case Report

A 56-year-old male patient presented to routine follow-up consultation 40 days after orthotopic liver transplantation from deceased donor. It was his second graft, due to failure related to ischemic cholangiopathy of the first one, implanted 9 months earlier. In the previous transplantation he


developed splenic artery steal syndrome, treated successfully with splenic artery coiling.

In the second transplant, hepatic arteries and portal veins of the donor and recipient were anastomosed end-to-end and bile duct reconstruction was performed with a duct-to-duct anastomosis. Intraoperative findings showed no abnormalities in the hepatic artery, portal vein, hepatic vein or bile duct.


In the hepatic Doppler ultrasound, performed at the 40th day consultation, a fluid collection in the hepatic hilum was noted, apparently of vascular origin, and an urgent abdominal CT was performed. The CT showed a large HAP, measuring 3 cm in diameter, near the hepatic artery anastomosis (Figure 1).

The hepatic transplantation and interventional radiology teams reviewed the case and discussed the options with the patient, recommending an endovascular approach.

The patient was taken to the angiography lab and digital subtraction angiography (DSA) confirmed the HAP (Figure 2A). Due to the site of the HAP, and suitable anatomy (no kinking or bifurcations), a stent-grafting with 2 covered stents (Advanta V12™ Balloon Expandable Covered Stent 5 x 22 mm, Getinge®, Gotenburg, Sweden) was performed (Figure 2B). First the right hepatic artery was reached with a hydrophilic guidewire (Terumo® 0,035" x 180 cm, Tokyo, Japan), allowing the catheterization with a 4F multipurpose




**Figure 1** – HAP. Abdominal angio-CT, with MIP and VR reformating, showing a large contrast enhancing pseudoaneurysm near the hepatic artery anastomosis (arrows in A and B). MIP - maximum intensity projection; VR - volume rendering.



**Figure 2** – DSA confirming the presence of a HAP (thick arrow in A). Stent grafting with 2 Advanta V12 Balloon Expandable Covered Stents 5 x 22 mm (arrows), showing good end-result, with HAP totally excluded (B). DSA - digital subtraction angiography; HAP - hepatic artery pseudoaneurysm.

catheter and the guide was replaced by a more rigid one (Starter™ 0,035" x 260 cm, J tip, Boston Scientific®, Massachusetts, USA). An introducer sheath (Destination™ 7F, 45 cm, Terumo®, Tokyo, Japan) was then positioned at the site of the anastomosis allowing the subsequent release of the first stent graft that did not completely exclude the pseudoaneurysm. Thus, the proximal portion of the stent graft was prolonged with a second partially overlapping stent, leading to the complete exclusion of the pseudoaneurysm.

A follow-up CT performed 5 days after stent placement showed good results, with stents in place and the HAP excluded (Figure 3). Antiplatelet medication with clopidogrel (75 mg) and low-dose acetylsalicylic acid (100 mg), was maintained during the following 6 months. Presently, at 10-month follow-up the patient did not present infection or hemorrhagic complications and the stent-graft is patent (Figure 4).



**Figure 3** – Abdominal angio-CT, with VR reformating, performed 5 days after the intervention, showing the stents in place (small arrows), with no thrombosis or sign of the HAP. There are also signs of previous venous embolization of a large left gastric vein with an amplatzer plug device (large arrow).



**Figure 4** – Abdominal angio-CT, with MIP reformating, performed at 10-month follow-up, showing patency of the stents (arrows).

---

## Discussion

The clinical manifestations of HAP vary from asymptomatic, to abdominal pain with fever, gastrointestinal bleeding (up to 25%) and hemorrhagic shock.<sup>1,2,3</sup>

Post-surgical surveillance ultrasound examination combined with color Doppler, has been shown to improve detection of vascular complications, with DSA still being the gold-standard imaging modality in the evaluation of an aneurysm. Several factors have been implicated in hepatic artery complications, including: technical imperfections at the anastomosis site and type of reconstruction, intimal dissection, kinking and repeated anastomosis.<sup>1</sup>

Treatment options consist of either interventional radiology with insertion of an arterial stent or coiling at the neck of the aneurysm and surgical intervention.<sup>1,2,4,5</sup> Superselective microcoil embolization has been recognized as an effective treatment in patients with extrahepatic pseudoaneurysms of the hepatic arteries.<sup>1,2,6</sup> Embolization is the treatment of choice in biopsy related intrahepatic pseudoaneurysms.<sup>1</sup>

The use of covered stents has some technical difficulties, namely in tortuous vessels, such as the hepatic artery due to low flexibility of the endoprosthesis. Not all vessels are adequate for stent placing, however, some strategies can be adopted, such as using a short endoprosthesis, a stiff guidewire and a long introducer sheath. Also, some

manufacturers provide more flexible stents (e.g. Gore® VIABAHN® Endoprosthesis), compatible with low profile guidewires (i.e. 0,018”), ideal for smaller and tortuous vessels or severe stenosis.

In the case we presented, the location of the HAP seemed suitable for the stents, with no kinking of the vessel. Hepatic artery patency was maintained, preserving arterial blood supply to the liver, which was of particular importance in this patient, who had already been subjected to a second graft placement after ischemic cholangiopathy. The gastroduodenal artery was also preserved, although sometimes it has to be excluded during the procedures, usually with no major consequences.

Stent graft implantation for the HAP treatment is associated with high rates of technical success and good short-term stent patency rates (81%), decreasing to 40% at mid-to-long-term follow-up.<sup>7</sup>

## Conclusion

Endovascular intervention of HAP should be regarded as the treatment of choice, either in order to stabilize an active bleed or to prevent it, preferably with flow preserving techniques such as the use of stent grafts.

---

### Ethical disclosures / Divulgações Éticas

*Conflicts of interest:* The authors have no conflicts of interest to declare.

*Conflitos de interesse:* Os autores declaram não possuir conflitos de interesse.

*Financing Support:* This work has not received any contribution, grant or scholarship.

*Suporte financeiro:* O presente trabalho não foi suportado por nenhum subsídio ou bolsa.

*Confidentiality of data:* The authors declare that they have followed the protocols of their work center on the publication of data from patients.

*Confidencialidade dos dados:* Os autores declaram ter seguido os protocolos do seu centro de trabalho acerca da publicação dos dados de doentes.

*Protection of human and animal subjects:* The authors declare that the procedures followed were in accordance with the regulations of the relevant clinical research ethics committee and with those of the Code of Ethics of the World Medical Association (Declaration of Helsinki).

*Proteção de pessoas e animais:* Os autores declaram que os procedimentos seguidos estavam de acordo com os regulamentos estabelecidos pelos responsáveis da Comissão de Investigação Clínica e Ética e de acordo com a Declaração de Helsínquia da Associação Médica Mundial.

### References

1. Karatzas T, Lykaki-Karatzas E, Webb M, et al. Vascular complications, treatment, and outcome following orthotopic liver transplantation. *Transplant Proc.* 1997;29:2853-5.

2. Marshall MM, Muiesan P, Srinivasan P, et al. Hepatic artery pseudoaneurysms following liver transplantation: incidence, presenting features and management. *Clin Radiol.* 2001;56:579-87.

3. Piardi T, Lhuair M, Bruno O, et al. Vascular complications following liver transplantation: a literature review of advances in 2015. *World J Hepatol.* 2016;8:36-57.

4. Paci E, Antico E, Candelari R, et al. Pseudoaneurysm of the common hepatic artery: treatment with a stent-graft. *Cardiovasc Intervent Radiol.* 2000;23:472-4.

5. Patel JV, Weston MJ, Kessel DO, et al. Hepatic artery pseudoaneurysm after liver transplantation: treatment with percutaneous thrombin injection. *Transplantation.* 2003;75:1755-7.

6. Reber PU, Baer HU, Patel AG, et al. Superselective microcoil embolization: treatment of choice in high-risk patients with extrahepatic pseudoaneurysms of the hepatic arteries. *J Am Coll Surg.* 1998;186:325-30.

7. Pedersoli F, Van den Bosch V, Sieben P et al. Stent graft placement by pseudoaneurysm of the hepatic arteries: efficacy and patency rate in follow-up. *Cardiovasc Intervent Radiol.* 2022;45:21-8.